Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

被引：0
|
作者：
Sorror, Mohamed L. [1 ]
Storer, Barry [1 ]
Sandmaier, Brenda M. [1 ]
Braunert, Leanthe [2 ]
Laport, Ginna G. [3 ]
Chauncey, Thomas [1 ,4 ]
Bredeson, Christopher [5 ]
Maziarz, Richard T. [6 ]
Pulsipher, Michael A. [7 ]
Agura, Edward [8 ]
Mans, Michael T. [9 ]
Vindelov, Lars [10 ]
Sahebi, Firoozeh [11 ]
McSweeney, Peter [12 ]
Bruno, Benedetto [13 ]
Langston, Amelia [14 ]
Storb, Rainer F. [1 ]
Maloney, David G. [1 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[2] Univ Leipzig, Leipzig, Germany
[3] Stanford Univ, Stanford, CA 94305 USA
[4] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[7] Univ Utah, Salt Lake City, UT USA
[8] Baylor Univ, Dallas, TX USA
[9] Rocky Mt Canc Ctr, Denver, CO USA
[10] Rigshosp, DK-2100 Copenhagen, Denmark
[11] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[12] Univ Colorado, Boulder, CO 80309 USA
[13] Univ Turin, Turin, Italy
[14] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：978 / 978
页数：1
相关论文
共 50 条
  • [31] Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia
    Motohashi, Kenji
    Fujisawa, Shin
    Doki, Noriko
    Kobayashi, Takeshi
    Mori, Takehiko
    Usuki, Kensuke
    Tanaka, Masatsugu
    Fujiwara, Shinichiro
    Kako, Shinichi
    Aoyama, Yasuyuki
    Onoda, Masahiro
    Yano, Shingo
    Gotoh, Moritaka
    Kanamori, Heiwa
    Takahashi, Satoshi
    Okamoto, Shinichiro
    LEUKEMIA & LYMPHOMA, 2018, 59 (06) : 1332 - 1337
  • [32] Practical Aspects of Allogeneic Hematopoietic Cell Transplantation for Patients with Poor-Risk Chronic Lymphocytic Leukemia
    Delgado, Julio
    Duarte, Rafael F.
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 161 - 172
  • [33] Risk factors for adverse outcome in patients with Chronic Lymphocytic Leukemia (CLL) undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT): A Retrospective EBMT Analysis
    Schetelig, J.
    de Wreede, L.
    Moreno, C.
    Andersen, N. Smedegaard
    van Gelder, M.
    Machaczka, M.
    Gramatzki, M.
    Dreger, P.
    Vitek, A.
    Karas, M.
    Michallet, M.
    Henseler, A.
    Bornhaeuser, M.
    Schoenland, S.
    Kroeger, N.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S107 - S108
  • [34] Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia
    Schetelig, Johannes
    Thiede, Christian
    Kiani, Alexander
    Platzbecker, Uwe
    Oelschlaegel, Uta
    Haenel, Matthias
    Geissler, Gaby
    Schwerdtfeger, Rainer
    Kolbe, Karin
    Kaufmann, Martin
    Zeis, Matthias
    Schaefer-Eckart, Kerstin
    Siegert, Wolfgang
    Ehninger, Gerhard
    BLOOD, 2009, 114 (22) : 1301 - 1301
  • [35] Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Kahl, Christoph
    Storer, Barry E.
    Sandmaier, Brenda M.
    Mielcarek, Marco
    Maris, Michael B.
    Blume, Karl G.
    Niederwieser, Dielger
    Chauncey, Thomas R.
    Forman, Stephen J.
    Agura, Edward
    Leis, Jose F.
    Bruno, Benedetto
    Langston, Amelia
    Pulsipher, Michael A.
    McSweeney, Peter A.
    Wade, James C.
    Epner, Elliot
    Petersen, Finn Bo
    Bethge, Wolfgang A.
    Maloney, David G.
    Storb, Rainer
    BLOOD, 2007, 110 (07) : 2744 - 2748
  • [36] Outcomes among patients with recurrent high-risk hematologic malignancy after nonmyeloablative versus myeloablative allogeneic hematopoietic cell transplantation.
    Mielcarek, Marco
    Martin, Paul J.
    Maloney, David G.
    Storb, Rainer
    Sandmaier, Brenda M.
    BLOOD, 2006, 108 (11) : 81A - 82A
  • [37] Impacts of comorbidities on outcomes of patients (pts) diagnosed with B-cell malignancies and treated with allogeneic hematopoietic cell transplantation (HCT) using nonmyeloablative (NM) vs myeloablative (M) conditioning.
    Sorror, Mohamed
    Sandmaier, Brenda M.
    Storer, Barry
    Maris, Michael B.
    Maloney, David G.
    Storb, Rainer
    BLOOD, 2006, 108 (11) : 165A - 166A
  • [38] Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors.
    Sorror, Mohamed L.
    Storer, Barry
    Sandmaier, Brenda M.
    Franke, Georg N.
    Laport, Ginna G.
    Chauncey, Thomas
    Agura, Edward
    Maris, Michael T.
    Wade, James
    Pulsipher, Michael A.
    Maziarz, Richard T.
    Sahebi, Firoozeh
    McSweeney, Peter
    Bruno, Benedetto
    Vindelov, Lars
    Yeager, Andrew M.
    Rezvani, Andrew
    Niederwieser, Dietger W.
    Blume, Karl G.
    Storb, Rainer F.
    Maloney, David G.
    BLOOD, 2010, 116 (21) : 553 - 553
  • [39] Long term follow up of allogeneic hematopoietic stem cell transplantation (ASCT) in chronic lymphocytic leukemia (CLL).
    Malhotra, P
    Hogan, WJ
    Litzow, MR
    Elliott, MA
    Dispenzieri, A
    Call, T
    Kay, NE
    Zent, C
    Gastineau, DA
    Ansell, SM
    Hayman, S
    Gertz, MA
    Lacy, MQ
    Porrata, LF
    Inwards, DJ
    Tefferi, A
    BLOOD, 2005, 106 (11) : 441B - 441B
  • [40] Hope for High-Risk Chronic Lymphocytic Leukemia Relapsing After Allogeneic Stem-Cell Transplantation
    Montserrat, Emili
    Dreger, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (14) : 1527 - +
12345